By engineering naturally existing arrestin domain-containing protein 1 (ARRDC1)-mediated microvesicles (known as ARMMs), Vesigen Therapeutics’ platform enables the effective delivery ...
Complications of viral vectors can be avoided with DNA plasmids, engineered vesicles, cell-penetrating proteins, and other nonviral alternatives ...
CAMBRIDGE, Mass., October 5, 2023 /Business Wire/ — Vesigen Therapeutics, Inc., a biotechnology company developing a novel non-viral delivery platform ...
CAMBRIDGE, Mass., September 7, 2023 /Business Wire/ — Vesigen Therapeutics, Inc., a biotechnology company developing a novel non-viral delivery platform ...
Engineered ARMMs efficiently deliver CRISPR/Cas9 complexes, base editing complexes and RNA therapeutics Additional presentations demonstrate biodistribution to a range of ...
CAMBRIDGE, Mass., May 2, 2023 /Business Wire/ — Vesigen Therapeutics, Inc., a biotechnology company developing a novel non-viral delivery platform ...